22 December 2016Genticel and Genkyotex Announce Intention to Enter into Strategic Combination, Genkyotex is a pioneer in discovery and development of NOX therapeutics
Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a biotechnology company developing innovative immunotherapies, and Genkyotex, a Swiss privately-held biopharmaceutical company and the leader in NOX therapies, announced today that Genticel has signed a contribution agreement with the shareholders of Genkyotex pursuant to which, subject to the approval of Genticel’s shareholders at a meeting expected to be held in the first quarter of 2017, Genkyotex’s shareholders will contribute in kind 100% of the Genkyotex share capital (on a fully diluted basis) to Genticel, which will issue new shares in remuneration for the contribution. Upon completion of the proposed transaction, Genkyotex’s shareholders will hold 80% of Genticel’s share capital and voting rights (on a non-diluted basis).
6 December 2016
Acquisition Adds Phase IIb Product, Clinical Candidates and Novel Discovery Platform To Sienna’s Growing Pipeline.
5 December 2016Wilson Therapeutics Announces that WTX101 Meets the Primary Endpoint in Phase 2 Study in Wilson Disease
Wilson Therapeutics AB (publ), announced today that the Phase 2 study of WTX101 (bis-choline tetrathiomolybdate; Decuprate®), an investigational first in class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease, met its primary endpoint. In the ITT population, 79% of patients achieved or maintained normalized levels of free copper, or experienced a reduction of at least 25% in free copper in blood from baseline, after 24 weeks of treatment with WTX101.
5 December 2016
4Tech Inc., a privately held clinical-stage company that is developing the breakthrough TriCinch™ System for repair of the Tricuspid heart valve, today announced the appointment of Michael Ennen, M.D., as President and Chief Executive Officer, effective immediately. Dr. Ennen succeeds co-founder Carine Schorochoff, who will continue to serve 4Tech as an advisor and board observer.
1 December 2016
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, infectious diseases and autoimmune diseases, was awarded Financing Deal of the Year at last night’s SCRIP awards at the Grosvenor House Hotel, Park Lane, London.